Jason Bednar
Stock Analyst at Piper Sandler
(2.29)
# 2,563
Out of 4,711 analysts
150
Total ratings
48.36%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Maintains: Overweight | $180 → $210 | $169.52 | +23.88% | 13 | Dec 18, 2024 | |
| NVCR NovoCure | Maintains: Overweight | $28 → $42 | $30.80 | +36.36% | 9 | Dec 13, 2024 | |
| PDCO Patterson Companies | Maintains: Neutral | $26 → $24 | $30.86 | -22.23% | 8 | Dec 6, 2024 | |
| KRMD KORU Medical Systems | Maintains: Overweight | $3 → $3.5 | $4.02 | -12.94% | 5 | Nov 14, 2024 | |
| SOLV Solventum | Maintains: Neutral | $71 → $75 | $66.83 | +12.23% | 2 | Nov 8, 2024 | |
| MDXH MDxHealth | Maintains: Overweight | $8 → $6 | $2.26 | +165.49% | 5 | Nov 7, 2024 | |
| NVST Envista Holdings | Maintains: Neutral | $16 → $17 | $18.70 | -9.09% | 10 | Oct 31, 2024 | |
| ALGN Align Technology | Maintains: Overweight | $285 → $275 | $211.06 | +30.29% | 27 | Oct 24, 2024 | |
| STE STERIS | Upgrades: Overweight | $230 → $260 | $207.49 | +25.31% | 8 | Oct 24, 2024 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $100 → $110 | $98.22 | +11.99% | 7 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $120 | $93.44 | +28.42% | 11 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.10 | +125.81% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $1 | $0.40 | +148.08% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $6.15 | +95.12% | 10 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 | $69.82 | +23.17% | 6 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $13 | $13.24 | -1.81% | 1 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $35 → $32 | $18.70 | +71.12% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $524.43 | -29.07% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.19 | +310.96% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $305 → $280 | $227.68 | +22.98% | 6 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $78.91 | +20.39% | 1 | Apr 19, 2023 |
Masimo
Dec 18, 2024
Maintains: Overweight
Price Target: $180 → $210
Current: $169.52
Upside: +23.88%
NovoCure
Dec 13, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $30.80
Upside: +36.36%
Patterson Companies
Dec 6, 2024
Maintains: Neutral
Price Target: $26 → $24
Current: $30.86
Upside: -22.23%
KORU Medical Systems
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $3.5
Current: $4.02
Upside: -12.94%
Solventum
Nov 8, 2024
Maintains: Neutral
Price Target: $71 → $75
Current: $66.83
Upside: +12.23%
MDxHealth
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $2.26
Upside: +165.49%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $16 → $17
Current: $18.70
Upside: -9.09%
Align Technology
Oct 24, 2024
Maintains: Overweight
Price Target: $285 → $275
Current: $211.06
Upside: +30.29%
STERIS
Oct 24, 2024
Upgrades: Overweight
Price Target: $230 → $260
Current: $207.49
Upside: +25.31%
Merit Medical Systems
Sep 9, 2024
Reiterates: Overweight
Price Target: $100 → $110
Current: $98.22
Upside: +11.99%
Aug 29, 2024
Reiterates: Overweight
Price Target: $115 → $120
Current: $93.44
Upside: +28.42%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.10
Upside: +125.81%
Aug 7, 2024
Maintains: Overweight
Price Target: $3.5 → $1
Current: $0.40
Upside: +148.08%
Aug 1, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $6.15
Upside: +95.12%
Jun 21, 2024
Reiterates: Overweight
Price Target: $86
Current: $69.82
Upside: +23.17%
May 21, 2024
Initiates: Neutral
Price Target: $13
Current: $13.24
Upside: -1.81%
May 3, 2024
Reiterates: Neutral
Price Target: $35 → $32
Current: $18.70
Upside: +71.12%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $524.43
Upside: -29.07%
Nov 10, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.19
Upside: +310.96%
Nov 10, 2023
Maintains: Overweight
Price Target: $305 → $280
Current: $227.68
Upside: +22.98%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $78.91
Upside: +20.39%